tiprankstipranks
MapLight Therapeutics, Inc. (MPLT)
NASDAQ:MPLT
US Market
MPLT
MapLight Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see MPLT full AI Analyst Report?

MapLight Therapeutics, Inc. (MPLT) Stock Forecast & Price Target

33 Followers
See the Price Targets and Ratings of:

MPLT Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
MapLight
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MPLT Stock 12 Month Forecast

Average Price Target

$33.20
▲(89.82% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for MapLight Therapeutics, Inc. in the last 3 months. The average price target is $33.20 with a high forecast of $52.00 and a low forecast of $20.00. The average price target represents a 89.82% change from the last price of $17.49.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","53":"$53","22.25":"$22.3","32.5":"$32.5","42.75":"$42.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,22.25,32.5,42.75,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.08,37.30461538461538,38.529230769230765,39.753846153846155,40.97846153846154,42.20307692307692,43.427692307692304,44.65230769230769,45.87692307692308,47.10153846153846,48.326153846153844,49.550769230769234,50.77538461538461,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.08,35.85846153846154,35.636923076923075,35.41538461538462,35.19384615384615,34.972307692307695,34.75076923076923,34.52923076923077,34.30769230769231,34.08615384615385,33.864615384615384,33.643076923076926,33.42153846153846,{"y":33.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.08,34.84307692307692,33.606153846153845,32.36923076923077,31.13230769230769,29.895384615384614,28.658461538461538,27.42153846153846,26.184615384615384,24.947692307692307,23.71076923076923,22.473846153846154,21.236923076923077,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.34,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.34,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.34,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.34,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.565,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.93,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.83,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.08,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$52.00Average Price Target$33.20Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MPLT
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$45→$26
Buy
48.66%
Upside
Reiterated
07/28/26
MapLight Therapeutics price target lowered to $26 from $45 at H.C. WainwrightMapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright
Morgan Stanley Analyst forecast on MPLT
Sean Laaman
Morgan Stanley
Morgan Stanley
$34→$21
Hold
20.07%
Upside
Downgraded
07/28/26
MapLight downgraded to Equal Weight from Overweight at Morgan StanleyMapLight downgraded to Equal Weight from Overweight at Morgan Stanley
Craig-Hallum Analyst forecast on MPLT
Adam Vogel
Craig-Hallum
Craig-Hallum
$40→$25
Buy
42.94%
Upside
Reiterated
07/28/26
MapLight Therapeutics price target lowered to $25 from $40 at Craig-HallumMapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum
Needham Analyst forecast on MPLT
Ami Fadia
Needham
Needham
$45
Buy
157.29%
Upside
Reiterated
07/27/26
Analyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target on Favorable Risk‑Reward and Alzheimer’s Pipeline Upside
Canaccord Genuity Analyst forecast on MPLT
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$43→$24
Buy
37.22%
Upside
Reiterated
07/27/26
MapLight Therapeutics price target raised to $43 from $35 at CanaccordMapLight Therapeutics price target raised to $43 from $35 at Canaccord
LifeSci Capital Analyst forecast on MPLT
Francois Brisebois
LifeSci Capital
LifeSci Capital
$45→$37
Buy
111.55%
Upside
Reiterated
07/27/26
Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)
BMO Capital Analyst forecast on MPLT
Malcolm Hoffman
BMO Capital
BMO Capital
$20
Buy
14.35%
Upside
Reiterated
07/27/26
Analysts Are Bullish on Top NA Stocks: Safe Pro Group, Inc. (SPAI), MapLight Therapeutics, Inc. (MPLT)
UBS Analyst forecast on MPLT
Ashwani Verma
UBS
UBS
$48→$52
Buy
197.31%
Upside
Assigned
07/21/26
Analysts' Top NA Picks: BKV Corporation (BKV), MapLight Therapeutics, Inc. (MPLT)
Raymond James Analyst forecast on MPLT
Tiago Fauth
Raymond James
Raymond James
$46
Buy
163.01%
Upside
Initiated
06/25/26
MapLight Therapeutics initiated with a Strong Buy at Raymond JamesMapLight Therapeutics initiated with a Strong Buy at Raymond James
Stifel Nicolaus Analyst forecast on MPLT
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$28→$36
Buy
105.83%
Upside
Reiterated
06/02/26
MapLight Therapeutics price target raised to $36 from $28 at StifelMapLight Therapeutics price target raised to $36 from $28 at Stifel
TD Cowen Analyst forecast on MPLT
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/14/26
Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), MapLight Therapeutics, Inc. (MPLT)
Leerink Partners Analyst forecast on MPLT
Marc Goodman
Leerink Partners
Leerink Partners
$30
Buy
71.53%
Upside
Initiated
11/21/25
MapLight Therapeutics initiated with an Outperform at LeerinkMapLight Therapeutics initiated with an Outperform at Leerink
Jefferies Analyst forecast on MPLT
Andrew Tsai
Jefferies
Jefferies
$32
Buy
82.96%
Upside
Initiated
11/21/25
Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MPLT
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$45→$26
Buy
48.66%
Upside
Reiterated
07/28/26
MapLight Therapeutics price target lowered to $26 from $45 at H.C. WainwrightMapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright
Morgan Stanley Analyst forecast on MPLT
Sean Laaman
Morgan Stanley
Morgan Stanley
$34→$21
Hold
20.07%
Upside
Downgraded
07/28/26
MapLight downgraded to Equal Weight from Overweight at Morgan StanleyMapLight downgraded to Equal Weight from Overweight at Morgan Stanley
Craig-Hallum Analyst forecast on MPLT
Adam Vogel
Craig-Hallum
Craig-Hallum
$40→$25
Buy
42.94%
Upside
Reiterated
07/28/26
MapLight Therapeutics price target lowered to $25 from $40 at Craig-HallumMapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum
Needham Analyst forecast on MPLT
Ami Fadia
Needham
Needham
$45
Buy
157.29%
Upside
Reiterated
07/27/26
Analyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target on Favorable Risk‑Reward and Alzheimer’s Pipeline Upside
Canaccord Genuity Analyst forecast on MPLT
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$43→$24
Buy
37.22%
Upside
Reiterated
07/27/26
MapLight Therapeutics price target raised to $43 from $35 at CanaccordMapLight Therapeutics price target raised to $43 from $35 at Canaccord
LifeSci Capital Analyst forecast on MPLT
Francois Brisebois
LifeSci Capital
LifeSci Capital
$45→$37
Buy
111.55%
Upside
Reiterated
07/27/26
Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)
BMO Capital Analyst forecast on MPLT
Malcolm Hoffman
BMO Capital
BMO Capital
$20
Buy
14.35%
Upside
Reiterated
07/27/26
Analysts Are Bullish on Top NA Stocks: Safe Pro Group, Inc. (SPAI), MapLight Therapeutics, Inc. (MPLT)
UBS Analyst forecast on MPLT
Ashwani Verma
UBS
UBS
$48→$52
Buy
197.31%
Upside
Assigned
07/21/26
Analysts' Top NA Picks: BKV Corporation (BKV), MapLight Therapeutics, Inc. (MPLT)
Raymond James Analyst forecast on MPLT
Tiago Fauth
Raymond James
Raymond James
$46
Buy
163.01%
Upside
Initiated
06/25/26
MapLight Therapeutics initiated with a Strong Buy at Raymond JamesMapLight Therapeutics initiated with a Strong Buy at Raymond James
Stifel Nicolaus Analyst forecast on MPLT
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$28→$36
Buy
105.83%
Upside
Reiterated
06/02/26
MapLight Therapeutics price target raised to $36 from $28 at StifelMapLight Therapeutics price target raised to $36 from $28 at Stifel
TD Cowen Analyst forecast on MPLT
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/14/26
Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), MapLight Therapeutics, Inc. (MPLT)
Leerink Partners Analyst forecast on MPLT
Marc Goodman
Leerink Partners
Leerink Partners
$30
Buy
71.53%
Upside
Initiated
11/21/25
MapLight Therapeutics initiated with an Outperform at LeerinkMapLight Therapeutics initiated with an Outperform at Leerink
Jefferies Analyst forecast on MPLT
Andrew Tsai
Jefferies
Jefferies
$32
Buy
82.96%
Upside
Initiated
11/21/25
Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential
Stocks with the Highest Top Analyst Consensus in the General Sector
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
CBRSCerebras Systems, Inc. Class A
FRVOFervo Energy Company Class A
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MapLight Therapeutics, Inc.

3 Months
Sumant KulkarniCanaccord Genuity
Success Rate
2/3 ratings generated profit
67%
Average Return
+22.87%
Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +22.87% per trade.
1 Year
Sumant KulkarniCanaccord Genuity
Success Rate
1/3 ratings generated profit
33%
Average Return
-3.40%
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -3.40% per trade.
2 Years
Sumant KulkarniCanaccord Genuity
Success Rate
1/3 ratings generated profit
33%
Average Return
-3.40%
Copying Sumant Kulkarni's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -3.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MPLT Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
1
2
6
7
12
Buy
0
1
8
14
19
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
3
14
21
32
In the current month, MPLT has received 31 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MPLT average Analyst price target in the past 3 months is 33.20.
Each month's total comprises the sum of three months' worth of ratings.

MPLT Financial Forecast

MPLT Earnings Forecast

Next quarter’s earnings estimate for MPLT is -$1.05 with a range of -$1.61 to -$0.76. The previous quarter’s EPS was -$37.18. MPLT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year MPLT has its overall industry.
Next quarter’s earnings estimate for MPLT is -$1.05 with a range of -$1.61 to -$0.76. The previous quarter’s EPS was -$37.18. MPLT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year MPLT has its overall industry.
No data currently available

MPLT Sales Forecast

Next quarter’s sales forecast for MPLT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MPLT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year MPLT has its overall industry.
Next quarter’s sales forecast for MPLT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MPLT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year MPLT has its overall industry.

MPLT Stock Forecast FAQ

What is MPLT’s average 12-month price target, according to analysts?
Based on analyst ratings, MapLight Therapeutics, Inc.’s 12-month average price target is 33.20.
    What is MPLT’s upside potential, based on the analysts’ average price target?
    MapLight Therapeutics, Inc. has 89.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MPLT a Buy, Sell or Hold?
          MapLight Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is MapLight Therapeutics, Inc.’s price target?
            The average price target for MapLight Therapeutics, Inc. is 33.20. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $52.00 ,the lowest forecast is $20.00. The average price target represents 89.82% Increase from the current price of $17.49.
              What do analysts say about MapLight Therapeutics, Inc.?
              MapLight Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of MPLT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.